U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06896253) titled 'Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis' on Feb. 12.
Brief Summary: Fulminant myocarditis (FM) is the most severe manifestation of acute myocarditis, an acute inflammatory myocardial disease most often triggered by viral infections.
Currently, the most accepted definition of FM requires acute illness, hemodynamic compromise due to cardiogenic shock, and need for hemodynamic support (inotropes and/or temporary mechanical circulatory support (t-MCS) in the absence of an ischemic cause or other pre-existing cardiomyopathies. Unfortunately, there is a paucity of evidence-based management strategies ...